No Data
No Data
Sichuan Kelun Pharmaceutical Obtains Drug Registration for Antibacterial Injection
Is Weakness In Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Sichuan Kelun Pharmaceutical (002422.SZ): The international business revenue in 2023 will be 2.588 billion yuan, consisting of infusion, non-infusion products, and R&D projects.
On July 18th, Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform that the company's international business revenue in 2023 will be 2.588 billion yuan, consisting of infusion, non-infusion products, and R&D projects. Geographically, overseas authorization income for R&D projects primarily comes from the United States, while overseas income from active pharmaceutical ingredients and formulation products primarily comes from Japan, India, Europe, Southeast Asia, South America, Africa and other countries or regions.
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
Sichuan Kelun Pharmaceutical (002422.SZ): The sales revenue of 0.034 billion yuan for the company's Dapoxetine hydrochloride in 2023.
On July 11th, Gelunhui reported that Sichuan Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform that the sales revenue of dapoxetine hydrochloride will be 0.034 billion yuan in 2023.
Kelun-Biotech to Buy Equipment From Sichuan Kelun Pharmaceutical's Unit
No Data